Alterations of the p53, p21, p16, p15 and RAS genes in childhood T-cell acute lymphoblastic leukemia
We investigated the alterations of the p53, p21, p16, p15 and RAS genes in childhood T-cell acute lymphoblastic leukemia (T-ALL) and T-ALL cell lines by polymerase chain reaction–single strand conformation polymorphism (PCR-SSCP) analysis and direct sequencing. Mutations of the p53 gene were found i...
Gespeichert in:
Veröffentlicht in: | Leukemia research 1999-02, Vol.23 (2), p.115-126 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | We investigated the alterations of the
p53, p21, p16, p15 and
RAS genes in childhood T-cell acute lymphoblastic leukemia (T-ALL) and T-ALL cell lines by polymerase chain reaction–single strand conformation polymorphism (PCR-SSCP) analysis and direct sequencing. Mutations of the
p53 gene were found in three of 57 (5%) patients at diagnosis, one of 14 (7%) patients at relapse and in 12 of 18 (67%) cell lines. In these 12 cell lines, four had more than two mutations of the
p53 gene. The
p53 mutations were found in four of five cell lines whose original fresh leukemic cells were simultaneously examined original fresh leukemic cells. However, only one of the four fresh leukemic cells had the same mutation. All patients with
p53 mutations in the course of disease died. Mutations of the
p21 gene were not identified in 71 fresh samples and in 18 cell lines.
N-RAS mutations were found in two of 57 (4%) fresh T-ALL patients at diagnosis, and four of 18 cell lines (22%), whereas no mutations were detected in any samples at relapse. Alterations of the
p16 gene were found in 18 of 47 (38%) patients at diagnosis and in seven of 14 (50%) at relapse. These differences were not statistically significant. There were no differences in the frequency of alteration of the
p16 and
p15 genes between event-free patients and the remaining patients. Furthermore, we found the methylation of
p16 gene in three of seven patients lacking homozygous deletions, suggesting higher frequency of p16 inactivation than previous reports in T-ALL. Interestingly, we found that one allele is inactivated by methylation and another allele had nonsense mutation in one cell line (KOPT-K1), resulting in loss of protein expression of p16. This type of p16 inactivation has not been so far reported in leukemia. We conclude that, (1)
p53 mutations are infrequent at diagnosis but tend to be associated with poor clinical outcome; (2)
RAS and
p21 mutations may not be involved in the pathogenesis of T-ALL; (3) not only frequent alterations of
p16 and
p15 genes but also methylation of
p16 gene are involved in initiating the leukemogenesis of T-ALLs, and (4) these 5 genes are independently involved in T-ALL. |
---|---|
ISSN: | 0145-2126 1873-5835 |
DOI: | 10.1016/S0145-2126(98)00146-5 |